Drug Profile

LX 101 - Innostellar Biotherapeutics

Alternative Names: LX-101 - Innostellar Biotherapeutics

Latest Information Update: 17 Jul 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

13 Jul 2025 Innostellar Biotherapeutics announces intention to submit BLA to NMPA for Retinal dystrophies
13 Sep 2023 Phase-III clinical trials in Retinal dystrophies (In adolescents, In children, In the elderly, In adults) in China (Subretinal) (NCT07054632)
12 Sep 2023 Innostellar Biotherapeutics initiates a phase I/II trial in Retinal dystrophies (In adolescents, In children, In adults, In the elderly) in China (Subretinal) (NCT06212297)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com